| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Methylprednisolone | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression). |
If used for local injections, monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency). |
|||
| Darunavir Methylprednisolone 972 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential for decreased plasma cortisol concentrations (e.g. Cushing's syndrome, adrenal suppression) |
Avoid combination or use alternative agents, particularly for long term use |
|||
| Elvitegravir Methylprednisolone 193 | Red: Avoid combination | Do not coadminister: Potential for increased levels of methylprednisolone | Potential for increased risk of adrenal insufficiency and Cushing's syndrome |
Do not coadminister if methylprednisolone being used for local injection. |
